VERAXA Biotech Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has taken a significant step forward by initiating cell line development for its lead BiTAC(R) T-cell engager (BiTAC(R)-TCE) program. The company has selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to support manufacturing development as the candidate advances toward IND/CTA-enabling studies. ATUM will apply its proprietary Leap-In Transposase(R) technology to generate stable clonal cell lines for VERAXA's lead therapeutic candidate. This collaboration represents an important development milestone, supporting manufacturing, analytical development, and nonclinical studies required before clinical testing. VERAXA's BiTAC(R) platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches. The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development.

The partnership with ATUM underscores VERAXA's commitment to advancing its pipeline of cancer immunotherapies. By leveraging ATUM's expertise in cell line engineering, VERAXA aims to optimize the production of its BiTAC(R)-TCE candidate, which targets specific tumor antigens while minimizing off-target effects. The company's proprietary platform utilizes bispecific T-cell engagers that bind to both cancer cells and T-cells, redirecting the immune system to attack tumors. Unlike traditional T-cell engagers that often cause severe toxicity due to systemic immune activation, VERAXA's BiTAC(R) technology incorporates selectivity mechanisms to focus the immune response on tumor sites. This approach could lead to safer and more effective treatments for patients with solid tumors and hematologic malignancies.

VERAXA's progress comes amid a broader push in the biotech industry to develop next-generation immunotherapies. The company has a robust pipeline of oncology candidates, and the recent expansion of its research facilities in Germany signals its readiness to scale up operations. With the initiation of cell line development, VERAXA is laying the groundwork for future clinical trials. The company's stock (NASDAQ: VRXA) has been closely watched by investors, and the latest news is expected to generate interest among those tracking oncology biotech developments. For more information, readers can visit the company's newsroom at https://ibn.fm/VRXA.